Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 3, 2006

 


Date of Report (Date of earliest event reported)

NPS PHARMACEUTICALS, INC.

 


(Exact name of registrant as specified in its charter)

 

 

                    Delaware       0-23272   87-0439579            

 


(State or other jurisdiction of
incorporation)
  (Commission File Number
 
)
 
  (I.R.S. Employer
Identification Number)

383 Colorow Drive

Salt Lake City, Utah 84108

 


(Address of principal executive offices)

 

(801) 583-4939

 


(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



ITEM 2.02. Results of Operations and Financial Condition.

The following information is furnished pursuant to Item 2.02, “Results of Operations and Financial Condition.” On August 3, 2006, NPS Pharmaceuticals, Inc. issued a press release announcing its 2006 second quarter operating results. The text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information in Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   

Description

99.1    Press Release dated August 3, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 3, 2006

   

NPS PHARMACEUTICALS, INC.

     

By:

      /S/    KEVIN J. ONTIVEROS
       

Kevin J. Ontiveros,

Vice President Corporate Law and

Assistant Corporate Secretary


EXHIBIT INDEX

 

Exhibit
Number
  

Description

99.1    Press Release issued by NPS Pharmaceuticals, Inc. on August 3, 2006.